TGFB1 and neoplasm: For example, TGF-β monoclonal antibodies, transforming growth factor-β receptor 1 (TGF-βR1) antagonists, and galectin-3 inhibitors can achieve anti-tumor effects by reducing the activation of CAFs and ECM cross-linking [73].